Cargando…

Targeting JUN, CEBPB, and HDAC3: A Novel Strategy to Overcome Drug Resistance in Hypoxic Glioblastoma

Hypoxia is a predominant feature in glioblastoma (GBM) and contributes greatly to its drug resistance. However, the molecular mechanisms which are responsible for the development of the resistant phenotype of GBM under hypoxic conditions remain unclear. To analyze the key pathways promoting therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Yixing, Liu, Bao, Feng, Lan, Sun, Binda, He, Shu, Yang, Yidong, Wu, Gang, E, Guoji, Liu, Chang, Gao, Yuqi, Zhang, Erlong, Zhu, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367651/
https://www.ncbi.nlm.nih.gov/pubmed/30775317
http://dx.doi.org/10.3389/fonc.2019.00033
_version_ 1783393845449326592
author Gao, Yixing
Liu, Bao
Feng, Lan
Sun, Binda
He, Shu
Yang, Yidong
Wu, Gang
E, Guoji
Liu, Chang
Gao, Yuqi
Zhang, Erlong
Zhu, Bo
author_facet Gao, Yixing
Liu, Bao
Feng, Lan
Sun, Binda
He, Shu
Yang, Yidong
Wu, Gang
E, Guoji
Liu, Chang
Gao, Yuqi
Zhang, Erlong
Zhu, Bo
author_sort Gao, Yixing
collection PubMed
description Hypoxia is a predominant feature in glioblastoma (GBM) and contributes greatly to its drug resistance. However, the molecular mechanisms which are responsible for the development of the resistant phenotype of GBM under hypoxic conditions remain unclear. To analyze the key pathways promoting therapy resistance in hypoxic GBM, we utilized the U87-MG cell line as a human GBM cell model and the human brain HEB cell line as a non-neoplastic brain cell model. These cell lines were cultured in the presence of 21, 5, and 1% O(2) for 24 h. We detected the changes in transcriptional profiling and analyzed the biological processes and functional interactions for the genes with different expression levels under different hypoxia conditions. The results indicated that those alterations of U87-MG cells presented specific transcriptional signature in response to diverse hypoxia levels. Gene ontology analysis revealed that the genes related to the DNA replication and cell cycle were suppressed, while the genes involved in tissue and system development to promote cancer development were activated following hypoxia. Moreover, functional interaction analysis suggested that the epigenetic regulator HDAC3 and the transcriptional factors CEBPB and JUN played a central role in organ and system developmental process pathway. Previous studies reported the global alterations caused by activation of HDAC3, CEBPB, and JUN could form the molecular basis of the resistance to chemotherapy and radiation therapy of hypoxic GBM. In our study, the significant growth inhibitory effect of temozolomide on hypoxic GBM cells could be promoted under downregulation of these genes. The experiment suggested that HDAC3, CEBPB, and JUN were closely involved in the drug-resistance phenotype of hypoxic GBM. In summary, we profiled the hypoxia-dependent changes in the transcriptome of the U87-MG cell line and the human brain cell line HEB to identify the transcriptional signatures of U87-MG cells and elucidate the role of hypoxia in the drug-resistant phenotype of GBM. Furthermore, we identified three key genes and explored their important roles in the drug resistance of hypoxic GBM.
format Online
Article
Text
id pubmed-6367651
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-63676512019-02-15 Targeting JUN, CEBPB, and HDAC3: A Novel Strategy to Overcome Drug Resistance in Hypoxic Glioblastoma Gao, Yixing Liu, Bao Feng, Lan Sun, Binda He, Shu Yang, Yidong Wu, Gang E, Guoji Liu, Chang Gao, Yuqi Zhang, Erlong Zhu, Bo Front Oncol Oncology Hypoxia is a predominant feature in glioblastoma (GBM) and contributes greatly to its drug resistance. However, the molecular mechanisms which are responsible for the development of the resistant phenotype of GBM under hypoxic conditions remain unclear. To analyze the key pathways promoting therapy resistance in hypoxic GBM, we utilized the U87-MG cell line as a human GBM cell model and the human brain HEB cell line as a non-neoplastic brain cell model. These cell lines were cultured in the presence of 21, 5, and 1% O(2) for 24 h. We detected the changes in transcriptional profiling and analyzed the biological processes and functional interactions for the genes with different expression levels under different hypoxia conditions. The results indicated that those alterations of U87-MG cells presented specific transcriptional signature in response to diverse hypoxia levels. Gene ontology analysis revealed that the genes related to the DNA replication and cell cycle were suppressed, while the genes involved in tissue and system development to promote cancer development were activated following hypoxia. Moreover, functional interaction analysis suggested that the epigenetic regulator HDAC3 and the transcriptional factors CEBPB and JUN played a central role in organ and system developmental process pathway. Previous studies reported the global alterations caused by activation of HDAC3, CEBPB, and JUN could form the molecular basis of the resistance to chemotherapy and radiation therapy of hypoxic GBM. In our study, the significant growth inhibitory effect of temozolomide on hypoxic GBM cells could be promoted under downregulation of these genes. The experiment suggested that HDAC3, CEBPB, and JUN were closely involved in the drug-resistance phenotype of hypoxic GBM. In summary, we profiled the hypoxia-dependent changes in the transcriptome of the U87-MG cell line and the human brain cell line HEB to identify the transcriptional signatures of U87-MG cells and elucidate the role of hypoxia in the drug-resistant phenotype of GBM. Furthermore, we identified three key genes and explored their important roles in the drug resistance of hypoxic GBM. Frontiers Media S.A. 2019-02-01 /pmc/articles/PMC6367651/ /pubmed/30775317 http://dx.doi.org/10.3389/fonc.2019.00033 Text en Copyright © 2019 Gao, Liu, Feng, Sun, He, Yang, Wu, E, Liu, Gao, Zhang and Zhu. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Gao, Yixing
Liu, Bao
Feng, Lan
Sun, Binda
He, Shu
Yang, Yidong
Wu, Gang
E, Guoji
Liu, Chang
Gao, Yuqi
Zhang, Erlong
Zhu, Bo
Targeting JUN, CEBPB, and HDAC3: A Novel Strategy to Overcome Drug Resistance in Hypoxic Glioblastoma
title Targeting JUN, CEBPB, and HDAC3: A Novel Strategy to Overcome Drug Resistance in Hypoxic Glioblastoma
title_full Targeting JUN, CEBPB, and HDAC3: A Novel Strategy to Overcome Drug Resistance in Hypoxic Glioblastoma
title_fullStr Targeting JUN, CEBPB, and HDAC3: A Novel Strategy to Overcome Drug Resistance in Hypoxic Glioblastoma
title_full_unstemmed Targeting JUN, CEBPB, and HDAC3: A Novel Strategy to Overcome Drug Resistance in Hypoxic Glioblastoma
title_short Targeting JUN, CEBPB, and HDAC3: A Novel Strategy to Overcome Drug Resistance in Hypoxic Glioblastoma
title_sort targeting jun, cebpb, and hdac3: a novel strategy to overcome drug resistance in hypoxic glioblastoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367651/
https://www.ncbi.nlm.nih.gov/pubmed/30775317
http://dx.doi.org/10.3389/fonc.2019.00033
work_keys_str_mv AT gaoyixing targetingjuncebpbandhdac3anovelstrategytoovercomedrugresistanceinhypoxicglioblastoma
AT liubao targetingjuncebpbandhdac3anovelstrategytoovercomedrugresistanceinhypoxicglioblastoma
AT fenglan targetingjuncebpbandhdac3anovelstrategytoovercomedrugresistanceinhypoxicglioblastoma
AT sunbinda targetingjuncebpbandhdac3anovelstrategytoovercomedrugresistanceinhypoxicglioblastoma
AT heshu targetingjuncebpbandhdac3anovelstrategytoovercomedrugresistanceinhypoxicglioblastoma
AT yangyidong targetingjuncebpbandhdac3anovelstrategytoovercomedrugresistanceinhypoxicglioblastoma
AT wugang targetingjuncebpbandhdac3anovelstrategytoovercomedrugresistanceinhypoxicglioblastoma
AT eguoji targetingjuncebpbandhdac3anovelstrategytoovercomedrugresistanceinhypoxicglioblastoma
AT liuchang targetingjuncebpbandhdac3anovelstrategytoovercomedrugresistanceinhypoxicglioblastoma
AT gaoyuqi targetingjuncebpbandhdac3anovelstrategytoovercomedrugresistanceinhypoxicglioblastoma
AT zhangerlong targetingjuncebpbandhdac3anovelstrategytoovercomedrugresistanceinhypoxicglioblastoma
AT zhubo targetingjuncebpbandhdac3anovelstrategytoovercomedrugresistanceinhypoxicglioblastoma